Cargando…

Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease

Factors predictive of skeletal-related events (SREs) in bone metastatic prostate cancer patients with hormone-refractory disease were investigated. We evaluated the frequency of SREs in 200 hormone-refractory patients consecutively observed at our Institution and followed until death or the last fol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berruti, A, Tucci, M, Mosca, A, Tarabuzzi, R, Gorzegno, G, Terrone, C, Vana, F, Lamanna, G, Tampellini, M, Porpiglia, F, Angeli, A, Scarpa, R M, Dogliotti, L
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2005
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361623/ https://www.ncbi.nlm.nih.gov/pubmed/16222309 http://dx.doi.org/10.1038/sj.bjc.6602767

Ejemplares similares

Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease.
por: Tampellini, M., et al.
Publicado: (1997)

Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience
por: Berruti, A, et al.
Publicado: (1999)

Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension.
por: Berruti, A., et al.
Publicado: (1996)

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases
por: Generali, D, et al.
Publicado: (2008)

The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients
por: Tampellini, M, et al.
Publicado: (2006)

Radical Prostatectomy and Intraoperative Radiation Therapy in High-Risk Prostate Cancer
por: Marchioro, Giansilvio, et al.
Publicado: (2012)

Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines
por: Berruti, A, et al.
Publicado: (2005)

Prognostic role of neuroendocrine differentiation in prostate cancer, putting together the pieces of the puzzle
por: Berruti, Alfredo, et al.
Publicado: (2010)

[−2]proPSA versus ultrasensitive PSA fluctuations over time in the first year from radical prostatectomy, in an high-risk prostate cancer population: A first report
por: De Luca, S., et al.
Publicado: (2016)

A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer
por: Collins, R, et al.
Publicado: (2006)

Parathyroid hormone 1-34 and skeletal anabolic action: The use of parathyroid hormone in bone formation
por: Osagie-Clouard, L., et al.
Publicado: (2017)

P1175: REAL LIFE OUTCOMES OF RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA: A SINGLE CENTRE EXPERIENCE
por: Dogliotti, I., et al.
Publicado: (2022)

bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer.
por: Apakama, I., et al.
Publicado: (1996)

FOLFOX activity in a rare case of metastatic colonic adenocarcinoma of the tongue: a case report
por: Zichi, Clizia, et al.
Publicado: (2018)

High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone
por: O'Sullivan, J M, et al.
Publicado: (2002)

Pretreatment haemoglobin levels significantly predict the tumour response to primary chemotherapy in human breast cancer
por: Bottini, A, et al.
Publicado: (2003)

THE RETICULO-ENDOTHELIAL SYSTEM AND HORMONE REFRACTORINESS
por: Gordon, Albert S., et al.
Publicado: (1939)

Satraplatin in the treatment of hormone-refractory metastatic prostate cancer
por: Armstrong, Andrew J, et al.
Publicado: (2007)

PB2132: COPANLISIB PLUS RITUXIMAB-BENDAMUSTINE FOR RELAPSED-REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RECRUITMENT UPDATE ON AN ONGOING PHASE II TRIAL OF THE FONDAZIONE ITALIANA LINFOMI (FIL_COPA-RB)
por: Novo, M., et al.
Publicado: (2022)

Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles
por: Kramer, G, et al.
Publicado: (2006)

On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2
por: Caffo, O., et al.
Publicado: (2020)

Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients
por: Bousquet, G, et al.
Publicado: (2011)

Multimodality treatment in hormone-refractory prostate cancer patients with bone metastases
por: Lam, Marnix G. E. H., et al.
Publicado: (2008)

Efficacy and safety of everolimus treatment in a hemodialysis patient with metastatic atypical bronchial carcinoid: case report and literature review
por: Brizzi, M. P., et al.
Publicado: (2018)

Role of Body Composition in the Prediction of Skeletal Fragility Induced by Hormone Deprivation Therapies in Cancer Patients
por: Dalla Volta, Alberto, et al.
Publicado: (2023)

Long term control of luteinized thecoma with sclerosing peritonitis with leuprorelin and tamoxifen treatment
por: Muratori, L., et al.
Publicado: (2019)

Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer
por: Tam, L, et al.
Publicado: (2007)

Cold affects the transcription of fatty acid desaturases and oil quality in the fruit of Olea europaea L. genotypes with different cold hardiness
por: Matteucci, M., et al.
Publicado: (2011)

Pathogenesis of prostate cancer and hormone refractory prostate cancer
por: Girling, J. S., et al.
Publicado: (2007)

Larynx organ preservation in subjects with hypopharynx-larynx cancer
por: Conticello, S, et al.
Publicado: (2010)

Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer
por: Bottini, A, et al.
Publicado: (2001)

Expanding the Role of Thyroid-Stimulating Hormone in Skeletal Physiology
por: Baliram, Ramkumarie, et al.
Publicado: (2017)

Patient-reported outcomes in refractory hormone-producing pituitary adenomas: an unmet need
por: van Trigt, Victoria R., et al.
Publicado: (2023)

Antiangiogenic Therapy in Clear Cell Renal Carcinoma (CCRC): Pharmacological Basis and Clinical Results
por: Comandone, Alessandro, et al.
Publicado: (2021)

Hormone refractory carcinoma prostate with peritoneal metastases and malignant ascites without skeletal involvement: A case report and review of literature
por: Benedict, Samuel P., et al.
Publicado: (2010)

Urology practice during the COVID-19 vaccination campaign
por: Ficarra, V., et al.
Publicado: (2021)

Explorando la perspectiva de los residentes sobre las modalidades y contenidos de aprendizaje inteligente para la educación virtual de urología: lección aprendida durante la pandemia de la COVID-19
por: Campi, R., et al.
Publicado: (2021)

Intermittent everolimus administration for malignant insulinoma
por: Baratelli, Chiara, et al.
Publicado: (2014)

Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer
por: Birtle, A J, et al.
Publicado: (2004)

Skeletal myopathy in patients with chronic heart failure: significance of anabolic-androgenic hormones
por: Josiak, Krystian, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_kb07bqe9s1vr1fl4euocfsnmfn